- Home
- NVNI vs RVPH Comparison
NVNI vs RVPH Comparison
Compare NVNI & RVPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NVNI
- RVPH
- Stock Information
- Founded
- NVNI 2019
- RVPH 2006
- Country
- NVNI Brazil
- RVPH United States
- Employees
- NVNI N/A
- RVPH N/A
- Industry
- NVNI
- RVPH Biotechnology: Pharmaceutical Preparations
- Sector
- NVNI
- RVPH Health Care
- Exchange
- NVNI Nasdaq
- RVPH Nasdaq
- Market Cap
- NVNI 31.5M
- RVPH 26.6M
- IPO Year
- NVNI N/A
- RVPH N/A
- Fundamental
- Price
- NVNI $0.49
- RVPH $0.46
- Analyst Decision
- NVNI
- RVPH Strong Buy
- Analyst Count
- NVNI 0
- RVPH 5
- Target Price
- NVNI N/A
- RVPH $9.00
- AVG Volume (30 Days)
- NVNI 12.4M
- RVPH 3.2M
- Earning Date
- NVNI 08-12-2025
- RVPH 08-13-2025
- Dividend Yield
- NVNI N/A
- RVPH N/A
- EPS Growth
- NVNI N/A
- RVPH N/A
- EPS
- NVNI N/A
- RVPH N/A
- Revenue
- NVNI $31,250,627.00
- RVPH N/A
- Revenue This Year
- NVNI $12.05
- RVPH N/A
- Revenue Next Year
- NVNI $15.02
- RVPH N/A
- P/E Ratio
- NVNI N/A
- RVPH N/A
- Revenue Growth
- NVNI 1491.58
- RVPH N/A
- 52 Week Low
- NVNI $0.14
- RVPH $0.30
- 52 Week High
- NVNI $12.19
- RVPH $4.28
- Technical
- Relative Strength Index (RSI)
- NVNI 57.10
- RVPH 46.82
- Support Level
- NVNI $0.35
- RVPH $0.44
- Resistance Level
- NVNI $0.83
- RVPH $0.53
- Average True Range (ATR)
- NVNI 0.08
- RVPH 0.04
- MACD
- NVNI 0.03
- RVPH 0.02
- Stochastic Oscillator
- NVNI 34.62
- RVPH 56.07
About NVNI Nvni Group Limited
Nvni Group Ltd is a holding company that conducts all of its business through Nuvini SA and Nuvini acquired companies. Nuvini S.A. acquires and operates software companies within SaaS markets in Brazil. Nuvini S.A. is the private serial software business acquirer in Brazil and intends to use funding and capital markets access to continue expanding its acquisition plans in Brazil and Latin America. The Company has determined that it has a single operating and reportable segment which is multi-vertical SaaS solution model.
About RVPH Reviva Pharmaceuticals Holdings Inc.
Reviva Pharmaceuticals Holdings Inc is a late-stage pharmaceutical company that discovers, develops, and seeks to commercialize therapeutics for diseases. The current pipeline of the company focuses on the central nervous system, inflammatory, and cardiometabolic diseases. The company uses a chemical genomics-driven technology platform and proprietary chemistry to develop new medicines. The company's pipeline currently has two drug candidates, Brilaroxazine (RP5063) which is intended to treat multiple neuropsychiatric indications, including schizophrenia, bipolar disorder, depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease and Parkinson's disease psychosis and its other drug candidate is RP1208.